Taken together, our findings indicate that PTK2B/FAK inhibitors could target important FLT3 mutation-associated niche interactions in AML, thus representing novel putative combination partners for FLT3 inhibitors. The gene discussed is FLT3; the disease is acute myeloid leukemia.